Literature DB >> 28969153

Substitutes of Prescription Medicines - A Review of Concerns Relevant to Doctors and Patients.

Jayant Kumar Kairi1, Ashok Kumar Sharma2.   

Abstract

A very large part of India's population fulfils its healthcare needs from government run healthcare delivery system which is free, contributory or highly subsidised. Use of medicines forms a large part of healthcare facility. As the number of medicines and brands are ever increasing in today's market, it is usual for pharmacy to substitute a generic instead of the prescribed brand or a different brand if the prescribed brand is not available. Depending on the type of substitute, it could fall under 'generic' or 'therapeutic' substitution. For any condition, there may be numerous medicines existing, some of which probably got introduced more recently, may be more expensive and erroneously perceived to act better than the earlier known medications for the same ailment. Also, due to very high number of medicines that are approved and available for use in the market, it is impossible to stock all the medicines in any pharmacy. Generic and therapeutic substitutions should be formalised and implemented by institutions, with the consent and cooperation of all the stake holders as guided by World Health Organisation. The advantages and limitations of medicine substitutes are discussed in the review.

Entities:  

Keywords:  Brand names; Generic; Therapeutic

Year:  2017        PMID: 28969153      PMCID: PMC5620794          DOI: 10.7860/JCDR/2017/28552.10439

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  24 in total

1.  Guidelines for therapeutic interchange-2004.

Authors:  Thomas Gray; Karen Bertch; Kimberly Galt; Michael Gonyeau; Emilie Karpiuk; Lance Oyen; Mary Jane Sudekum; Lee C Vermeulen
Journal:  Pharmacotherapy       Date:  2005-11       Impact factor: 4.705

2.  The emerging role of biosimilar epoetins in nephrology in the United States.

Authors:  Steven Fishbane; Hitesh H Shah
Journal:  Am J Kidney Dis       Date:  2015-01-10       Impact factor: 8.860

Review 3.  Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses.

Authors:  Costas Thomopoulos; Gianfranco Parati; Alberto Zanchetti
Journal:  J Hypertens       Date:  2015-07       Impact factor: 4.844

4.  Effect of atenolol vs metoprolol succinate on vascular function in patients with hypertension.

Authors:  Kevin S Heffernan; Ramya Suryadevara; Eshan A Patvardhan; Paula Mooney; Richard H Karas; Jeffrey T Kuvin
Journal:  Clin Cardiol       Date:  2011-01       Impact factor: 2.882

Review 5.  Efficacy and safety of innovator versus generic drugs in patients with epilepsy: a systematic review.

Authors:  Ripple Talati; Jennifer M Scholle; Olivia P Phung; Erika L Baker; William L Baker; Ajibade Ashaye; Jeffrey Kluger; Craig I Coleman; C Michael White
Journal:  Pharmacotherapy       Date:  2012-04       Impact factor: 4.705

6.  Generic and therapeutic substitutions in the UK: are they a good thing?

Authors:  Martin G Duerden; Dyfrig A Hughes
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

7.  Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors.

Authors:  Baptist Gallwitz
Journal:  Ther Adv Endocrinol Metab       Date:  2013-06       Impact factor: 3.565

8.  Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.

Authors:  S Oparil; D Williams; S G Chrysant; T C Marbury; J Neutel
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 Sep-Oct       Impact factor: 3.738

9.  Olmesartan is More Effective Than Other Angiotensin Receptor Antagonists in Reducing Proteinuria in Patients With Chronic Kidney Disease Other Than Diabetic Nephropathy.

Authors:  Takashi Ono; Toru Sanai; Yoshito Miyahara; Ritsuya Noda
Journal:  Curr Ther Res Clin Exp       Date:  2013-06

Review 10.  Potential Clinical and Economic Impact of Switching Branded Medications to Generics.

Authors:  Robert J Straka; Denis J Keohane; Larry Z Liu
Journal:  Am J Ther       Date:  2017-05       Impact factor: 2.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.